Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values

[1]  Mats O. Karlsson,et al.  Handling Data Below the Limit of Quantification in Mixed Effect Models , 2009, The AAPS Journal.

[2]  Mats O. Karlsson,et al.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  Vinod P. Shah,et al.  Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.

[4]  Courtney V. Fletcher,et al.  Impact of censoring data below an arbitrary quantification limit on structural model misspecification , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  R. Straubinger,et al.  Ultra-sensitive quantification of corticosteroids in plasma samples using selective solid-phase extraction and reversed-phase capillary high-performance liquid chromatography/tandem mass spectrometry. , 2007, Analytical chemistry.

[6]  Mats O. Karlsson,et al.  Impact of Omission or Replacement of Data Below the Limit of Quantification on Parameter Estimates in a Two-Compartment Model , 2002, Pharmaceutical Research.

[7]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  C. Gerbeau,et al.  Evaluation of Pharmacokinetic Studies: Is It Useful to Take into Account Concentrations Below the Limit of Quantification? , 1996, Pharmaceutical Research.

[9]  A. B. J. Nix,et al.  Assay detection limits: concept, definition, and estimation , 2004, European Journal of Clinical Pharmacology.

[10]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[11]  A. Chow,et al.  Single‐Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen‐Activated Protein Kinase Inhibitor: A First‐in‐Human Study , 2003, Journal of clinical pharmacology.

[12]  W. Jusko,et al.  Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles , 2000, Biopharmaceutics & drug disposition.

[13]  N. Pyszczynski,et al.  Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. , 1994, Journal of chromatography. B, Biomedical applications.

[14]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects , 1989, Clinical pharmacology and therapeutics.